Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of Thermo Fisher Scientific are up 0.81% at $670.67. The company is worth $247.98B, number 59 out of 300 on our list.
Over the past 52 weeks it has traded between $434.50 and $681.55, so it sits 1.6% below the top of that range. Holders are ahead 43.7% over twelve months, and up 36.3% across the last three months.
On the chart it holds above both the 50-day ($598.47) and 200-day ($538.56) moving averages; RSI is 69, and the last 30 sessions moved at roughly 25% annualized volatility.
Revenue for the quarter ended Jun 2026 was $11.99B, up 10.5% from a year earlier, with $1.74B of net profit (a 15.0% margin).
Buyers are paying 36.1 times trailing earnings, 15% above its five-year average of 31.5. The median for its industry group is 20.9.
18 analysts follow the stock and the average call is "buy". The mean target, $639.88, sits 4.6% under where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Thermo Fisher Scientific supplies lab instruments, reagents and services to drug companies, hospitals and researchers.
What tends to move it. Biopharma spending and research funding drive orders, and acquisitions add growth.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +6.9% | Bullish |
| Price vs 50-day average | +12.1% | Bullish |
| Price vs 200-day average | +24.5% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 68.6 | Bullish |
| MACD (12,26,9) | 16.90 | Bullish |
| Bollinger band position | 100% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 63rd percentile, 5-year average 31.5x
#2187 of 2977 stocks by PE (1 = cheapest)
Below its usual level · 36th percentile, 5-year average 4.6x
#4091 of 5303 stocks by PB (1 = cheapest)
Around its usual level · 53rd percentile, 5-year average 4.9x
#3811 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$35.40M (8 inflow days, 12 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 14.2% a year.
$670.67 is the latest print for TMO, a move of +0.81% against yesterday's close of $665.30. Today's low and high so far: $655.95 and $681.55.
Equity value comes to $247.98B at the current price. By that measure it is number 59 of the 300 names in our coverage.
Buyers pay 36.1 times the last twelve months of profit (EPS $17.74). Averaged over five years the multiple has been 31.5, and today's level ranks in the 63rd percentile of its own history.
The year's floor is $434.50 and the ceiling $681.55. Shares are 1.6% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.27% yield; the latest ex-dividend date was September 15, 2026.
Of 18 analysts, 83% say buy, 17% hold and 0% sell. Price targets average $639.88, with the most cautious at $520.00 and the most optimistic at $748.00.
Thermo Fisher Scientific supplies lab instruments, reagents and services to drug companies, hospitals and researchers.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.